Juvenile myelomonocytic leukemia radiation therapy: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
|||
| Line 12: | Line 12: | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 16:40, 9 August 2012
|
Juvenile myelomonocytic leukemia Microchapters |
|
Differentiating Juvenile myelomonocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Juvenile myelomonocytic leukemia radiation therapy On the Web |
|
American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia radiation therapy |
|
Juvenile myelomonocytic leukemia radiation therapy in the news |
|
Risk calculators and risk factors for Juvenile myelomonocytic leukemia radiation therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Radiation/Radiotherapy
Radiation to the spleen does not generally result in a decrease in spleen size or reduction of platelet transfusion requirement.
Conditioning regimen
The COG JMML Study involves 8 rounds of total-body irradiation (TBI) and doses of cyclophosphamide to prepare the JMML child’s body for bone marrow transplant. Use of TBI is controversial, though, because of the possibility of late side-effects such as slower growth, sterility, learning disabilities, and secondary cancers, and the fact that radiation can have devastating effects on very young children. It is used in this study, however, due to the concern that chemotherapy alone might not be enough to kill dormant JMML cells. The EWOG-MDS JMML Study includes busulfan in place of TBI due to its own research findings that appeared to show that busulfan was more effective against leukemia in JMML than TBI. The EWOG-MDS study also involves cyclophosphamide and melphalan in its conditioning regimen.